Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-nimotuzumab PET Imaging in EGFR Positive Cancers
NCT04235114Phase 2Recruiting
- Sponsor
- University of Saskatchewan
- Start
- Feb 2020
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of 89Zr-DFO-nimotuzumab in lung cancer and colorectal cancer (CRC) (3 arms), sponsored by University of Saskatchewan. Primary endpoint: Observation of differences in 89Zr-DFO-nimotuzumab uptake between tumors and normal tissues at Day 7. Started Feb 2020; status: recruiting.
02
Drugs
89Zr-DFO-nimotuzumab
03
Conditions
lung cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04235114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235114.